<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124902</url>
  </required_header>
  <id_info>
    <org_study_id>201404107</org_study_id>
    <secondary_id>1U24CA209837-01A1</secondary_id>
    <nct_id>NCT02124902</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity</brief_title>
  <official_title>A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neoimmune Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm open label phase II study in women with clinical stage 2 or 3 triple&#xD;
      negative breast cancer to assess the anti-tumor activity (in terms of pathologic complete&#xD;
      response rate) of neoadjuvant docetaxel in combination with carboplatin. Patient derived&#xD;
      xenografts will also be developed simultaneously for the purposes of genoproteomic analysis.&#xD;
&#xD;
      Please note that Baylor College of Medicine (BCM) has a parallel study the same as this&#xD;
      study. Baylor is expected to enroll approximately 19 participants that have complied with the&#xD;
      inclusion and exclusion criteria for this study (excluded participants from BCM will include&#xD;
      male participants or participants with inflammatory breast cancer). The investigators will&#xD;
      pool participants and data from the BCM study and the study at Washington University School&#xD;
      of Medicine. Pooling the data will potentially improve statistical power.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 7, 2014</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) rate</measure>
    <time_frame>At the time of surgery (surgery will take place 3-5 weeks after completion of treatment and estimated treatment length is 18 weeks)</time_frame>
    <description>pCR rate will be calculated with 95% CI and will be tested against the reference pCR rate of 35% with standard chemotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Triple Negative Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Washington University: Neoadjuvant docetaxel and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion. A total of 6 cycles will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baylor: Neoadjuvant docetaxel and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Baylor: Neoadjuvant docetaxel and carboplatin</arm_group_label>
    <arm_group_label>Washington University: Neoadjuvant docetaxel and carboplatin</arm_group_label>
    <other_name>Docefrez®, Taxotere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Baylor: Neoadjuvant docetaxel and carboplatin</arm_group_label>
    <arm_group_label>Washington University: Neoadjuvant docetaxel and carboplatin</arm_group_label>
    <other_name>Paraplatin, Paraplatin-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FDG-PET/MR</intervention_name>
    <description>Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)&#xD;
This is not optional for final 30 participants enrolled on the study</description>
    <arm_group_label>Baylor: Neoadjuvant docetaxel and carboplatin</arm_group_label>
    <arm_group_label>Washington University: Neoadjuvant docetaxel and carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed AJCC7 clinical stage II or III breast cancer with complete surgical&#xD;
             excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal.&#xD;
&#xD;
          -  Patients with PR+ tumors are allowed.&#xD;
&#xD;
          -  HER2 negative by FISH or IHC staining 0 or 1+.&#xD;
&#xD;
          -  ER less than Allred score of 3 or less than 1% positive staining cells in the invasive&#xD;
             component of the tumor&#xD;
&#xD;
          -  Tumor size at least 2cm in one dimension by clinical or radiographic exam (WHO&#xD;
             criteria). Patients with palpable lymph nodes may be enrolled regardless of tumor&#xD;
             size.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Normal bone marrow and organ function as defined below:&#xD;
&#xD;
               -  Leukocytes ≥ 3,000/mcL&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mcl&#xD;
&#xD;
               -  Platelets ≥ 100,000/mcl&#xD;
&#xD;
               -  Serum bilirubin within (or under ) normal limits (OR total bilirubin ≤ 3.0 x IULN&#xD;
                  with direct bilirubin within normal range in patients with well documented&#xD;
                  Gilbert Syndrome)&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) within (or under ) normal limits&#xD;
&#xD;
               -  Creatinine clearance ≥ 60 mL/min/1.73 m2&#xD;
&#xD;
          -  Patients may be pre- or post-menopausal. Women of childbearing potential must agree to&#xD;
             use adequate contraception (hormonal or barrier method of birth control, abstinence)&#xD;
             prior to study entry and for the duration of study participation. Should a woman&#xD;
             become pregnant or suspect she is pregnant while participating in this study, she must&#xD;
             inform her treating physician immediately.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
          -  Able to tolerate PET/MRI with intravenous contrast administration and must complete&#xD;
             the applicable MRI screening evaluation form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy for the indexed breast cancer.&#xD;
&#xD;
          -  A history of other malignancy ≤ 5 years previous with the exception of basal cell or&#xD;
             squamous cell carcinoma of the skin which were treated with local resection only or&#xD;
             carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Patients with bilateral or inflammatory breast cancer.&#xD;
&#xD;
          -  Currently receiving any other investigational agents.&#xD;
&#xD;
          -  A history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to docetaxel or carboplatin.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Pregnant and/or breastfeeding. Patient must have a negative serum pregnancy test&#xD;
             within 7 days of study entry if premenopausal.&#xD;
&#xD;
          -  Known HIV-positivity.&#xD;
&#xD;
          -  Sentinel lymph node biopsy&#xD;
&#xD;
          -  Renal insufficiency (glomerular filtration rate (GFR) &lt; 30 mL/min/1.73 m2) measured&#xD;
             within the past 60 days which precludes safe administration of the contrast agent&#xD;
&#xD;
          -  On dialysis&#xD;
&#xD;
          -  Prior allergic reaction to gadolinium-based MR contrast agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Foluso Ademuyiwa, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

